BACKGROUND/AIMS: The objective of this study was to assess in vivo gene therapy of uterine leiomyomas in the Eker rat model using adenovirus (Ad)-mediated delivery of herpes simplex virus 1 thymidine kinase gene (HSV1TK) followed by ganciclovir (GCV) treatment. METHODS: We randomized 27 female Eker rats with MRI-confirmed uterine leiomyomas to a single treatment with direct intra-tumor injection of Ad-HSV1TK/GCV, Ad-LacZ/GCV, or medium alone. Samples were collected from tumors, other body organs, and blood at 10, 20, and 30 days after treatment to assess the safety and efficacy of the treatment. RESULTS: Ad-HSV1TK/GCV treatment significantly decreased uterine fibroid volume by 75 +/- 16, 58.7 +/- 6.3, and 67.5 +/- 27.5%, of the pretreatment volume at days 10, 20, and 30, respectively. Ad-HSV1TK/GCV increased caspase-3 activity, Bax expression, and TUNEL apoptosis marker, and it decreased cyclin D1, PCNA, Bcl2, and PARP protein expressions. Ad transfection induced local CD4+ and CD8+ infiltration and serum anti-Ad antibodies. Additionally, Ad transfection was tumor-localized and safe to non-target tissues. CONCLUSION: These studies demonstrate a marked efficiency and high safety for the Ad-HSV1TK/GCV therapeutic approach in the context of Eker rat uterine leiomyomas and provide essential preclinical data for the development of Ad-HSV1TK/GCV gene therapy for uterine fibroids.
BACKGROUND/AIMS: The objective of this study was to assess in vivo gene therapy of uterine leiomyomas in the Eker rat model using adenovirus (Ad)-mediated delivery of herpes simplex virus 1 thymidine kinase gene (HSV1TK) followed by ganciclovir (GCV) treatment. METHODS: We randomized 27 female Eker rats with MRI-confirmed uterine leiomyomas to a single treatment with direct intra-tumor injection of Ad-HSV1TK/GCV, Ad-LacZ/GCV, or medium alone. Samples were collected from tumors, other body organs, and blood at 10, 20, and 30 days after treatment to assess the safety and efficacy of the treatment. RESULTS: Ad-HSV1TK/GCV treatment significantly decreased uterine fibroid volume by 75 +/- 16, 58.7 +/- 6.3, and 67.5 +/- 27.5%, of the pretreatment volume at days 10, 20, and 30, respectively. Ad-HSV1TK/GCV increased caspase-3 activity, Bax expression, and TUNEL apoptosis marker, and it decreased cyclin D1, PCNA, Bcl2, and PARP protein expressions. Ad transfection induced local CD4+ and CD8+ infiltration and serum anti-Ad antibodies. Additionally, Ad transfection was tumor-localized and safe to non-target tissues. CONCLUSION: These studies demonstrate a marked efficiency and high safety for the Ad-HSV1TK/GCV therapeutic approach in the context of Eker rat uterine leiomyomas and provide essential preclinical data for the development of Ad-HSV1TK/GCV gene therapy for uterine fibroids.
Authors: W R Smythe; H C Hwang; A A Elshami; K M Amin; S L Eck; B L Davidson; J M Wilson; L R Kaiser; S M Albelda Journal: Ann Surg Date: 1995-07 Impact factor: 12.969
Authors: S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham Journal: Cancer Res Date: 1993-11-01 Impact factor: 12.701
Authors: Kerry Byrnes; Benjamin D L Li; Neal Holm; Jie Li; Yoshi Okadata; Arrigo De Benedetti; A Nedeljkovic-Kurepa; Michael Mathis; Quyen D Chu Journal: Surgery Date: 2007-08 Impact factor: 3.982
Authors: M Ghadami; S A Salama; N Khatoon; R Chilvers; M Nagamani; P J Chedrese; A Al-Hendy Journal: Mol Hum Reprod Date: 2007-12-14 Impact factor: 4.025
Authors: M Ghadami; E El-Demerdash; S A Salama; A A Binhazim; A E Archibong; X Chen; B R Ballard; M R Sairam; A Al-Hendy Journal: Mol Hum Reprod Date: 2010-01-19 Impact factor: 4.025
Authors: Shahinaz Mahmood Shalaby; Mostafa K Khater; Aymara Mas Perucho; Sara A Mohamed; Inas Helwa; Archana Laknaur; Iryna Lebedyeva; Yutao Liu; Michael P Diamond; Ayman A Al-Hendy Journal: Fertil Steril Date: 2016-03-25 Impact factor: 7.329